Rare / orphan disease drugs

Discover the landscape of Rare / orphan disease drugs in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and intelligence on Rare / orphan disease drugs, helping you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

EyePoint's DURAVYU Misses Primary Endpoint in Phase III LUCIA Trial for Wet AMD – Non‑Inferiority vs. Aflibercept Not Achieved; Key Secondary Endpoints Met
CompanyDrug

EyePoint’s DURAVYU Misses Primary Endpoint in Phase III LUCIA Trial for Wet AMD – Non‑Inferiority vs. Aflibercept Not Achieved; Key Secondary Endpoints Met

Betta Pharmaceuticals (SHE: 300558) announced that its partner EyePoint Pharmaceuticals (NASDAQ: EYPT) disclosed data from LUCIA, the second pivotal Phase III clinical trial evaluating EYP‑1901 (DURAVYU), an investigational vorolanib ophthalmic…

Eli Lilly's Omvoh Delivers First One‑Year Phase 3 Readout in Pediatric Ulcerative Colitis – 50 % Clinical Remission at Week 52 in SHINE‑2

Eli Lilly’s Omvoh Delivers First One‑Year Phase 3 Readout in Pediatric Ulcerative Colitis – 50 % Clinical Remission at Week 52 in SHINE‑2

Insilico Medicine Earns Milestone Payment from Servier – First Oncology Program Hits Early‑Stage Drug Discovery Mark on Pharma.AI Platform

Insilico Medicine Earns Milestone Payment from Servier – First Oncology Program Hits Early‑Stage Drug Discovery Mark on Pharma.AI Platform

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Company

Gritgen Therapeutics Commences Operations of Commercial GMP Facilities in Suzhou

CompanyDrug

GenFleet Therapeutics’ CDK9 Inhibitor SLS009 Earns Orphan Drug Status for AML

CompanyDrug

Shanghai BDgene’s BD112 Earns Orphan Drug Designation from US FDA for Huntington’s Disease

CompanyDeals

Alphamab Oncology Enters Licensing Agreement with Grand Life Sciences for KN057 in Greater China

CompanyDrug

Sanofi’s Nexviazyme Approved in China as Enzyme Replacement Therapy for Pompe Disease

CompanyDrug

Amicus Therapeutics Secures FDA Approval for Pombiliti and Opfolda Combination Therapy

CompanyDeals

Novo Nordisk and Evotec Launch LAB eN² to Accelerate Drug Discovery for Rare Diseases

CompanyDrug

Sanofi’s Altuviiio Receives Marketing Approval from Japan’s MHLW for Hemophilia A Treatment

Show More